Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Atorvastatin | Case report

Rhabdomyolysis induced by rosuvastatin combined with entecavir: a case report

Authors: Wen Wang, Xu Lu, Chengbo Li, Wei Teng, Wei Cui

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

Rhabdomyolysis is a serious and potentially life threatening condition that can be caused by drugs. We report a case of acute hepatitis B with rhabdomyolysis after treatment with rosuvastatin and entecavir.

Case presentation

A 72-year-old female was admitted to our hospital due to acute hepatitis B infection. She had taken atorvastatin for 3 months before being admitted to our hospital. After being administered entecavir (ETV) and rosuvastatin to replace atorvastatin, she suffered from muscle pain in both lower limbs and was diagnosed with rhabdomyolysis. After discontinuation of the two drugs, the patient's symptoms subsided and creatine kinase levels returned to normal. We hypothesize that the rhabdomyolysis was caused by the combination of rosuvastatin and ETV.

Conclusions

We suggest that patients who use rosuvastatin and ETV be made aware of the complication of rhabdomyolysis.
Literature
1.
go back to reference Zutt R, van der Kooi AJ, Linthorst GE, Wanders RJ, Verschuuren JJ, de Visser M. Recurrent rhabdomyolysis: screening for underlying disease. Ned Tijdschr Geneeskd. 2010;154:A2290.PubMed Zutt R, van der Kooi AJ, Linthorst GE, Wanders RJ, Verschuuren JJ, de Visser M. Recurrent rhabdomyolysis: screening for underlying disease. Ned Tijdschr Geneeskd. 2010;154:A2290.PubMed
2.
go back to reference Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore). 2005;84(6):377–85.CrossRef Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore). 2005;84(6):377–85.CrossRef
3.
go back to reference Khan FY. Rhabdomyolysis: a review of the literature. Neth J Med. 2009;67(9):272–83.PubMed Khan FY. Rhabdomyolysis: a review of the literature. Neth J Med. 2009;67(9):272–83.PubMed
4.
go back to reference Brewer HB Jr. Benefit–risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol. 2003;92(4B):23K-29K.CrossRef Brewer HB Jr. Benefit–risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol. 2003;92(4B):23K-29K.CrossRef
5.
go back to reference Ramachandran R, Wierzbicki AS. Statins, muscle disease and mitochondria. J Clin Med. 2017;6(8):75.CrossRef Ramachandran R, Wierzbicki AS. Statins, muscle disease and mitochondria. J Clin Med. 2017;6(8):75.CrossRef
Metadata
Title
Rhabdomyolysis induced by rosuvastatin combined with entecavir: a case report
Authors
Wen Wang
Xu Lu
Chengbo Li
Wei Teng
Wei Cui
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07254-0

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.